GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| No information available. |
Summary of Clinical Use ![]() |
| Olatorepatide (HS-20094) was progressed to clinical evaluations as a once-weekly injectable agent for the treatment of overweight/obesity and/or type 2 diabetes. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT07431086 | Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US | Phase 2 Interventional | Regeneron Pharmaceuticals | ||
| NCT06839664 | A Study of HS-20094 in Chinese Adults with Overweight or Obesity | Phase 3 Interventional | Jiangsu Hansoh Pharmaceutical Co., Ltd. | ||
| NCT07156500 | A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone | Phase 3 Interventional | Jiangsu Hansoh Pharmaceutical Co., Ltd. | ||
| NCT07156539 | A Phase 3 Study of HS-20094 in Patients With T2DM | Phase 3 Interventional | Jiangsu Hansoh Pharmaceutical Co., Ltd. | ||